Ameriprise
OCUL icon

Ameriprise’s Ocular Therapeutix OCUL Stock Holding History

Ameriprise’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$353K Sell
35,980
-6,553
-15% -$59.4K ﹤0.01% 3774
2026
Q1 		$360K Sell
42,533
-353,058
-89% -$3.36M ﹤0.01% 3704
2025
Q4 		$4.8M Sell
395,591
-159,554
-29% -$1.94M ﹤0.01% 2463
2025
Q3 		$6.49M Buy
555,145
+322,259
+138% +$3.85M ﹤0.01% 2237
2025
Q2 		$2.16M Buy
232,886
+164,741
+242% +$1.29M ﹤0.01% 2917
2025
Q1 		$500K Sell
68,145
-21,627
-24% -$166K ﹤0.01% 3484
2024
Q4 		$767K Buy
89,772
+40,700
+83% +$397K ﹤0.01% 3358
2024
Q3 		$427K Buy
49,072
+12,529
+34% +$103K ﹤0.01% 3538
2024
Q2 		$250K Buy
36,543
+4,807
+15% +$29.7K ﹤0.01% 3639
2024
Q1 		$289K Buy
31,736
+2,736
+9% +$19.4K ﹤0.01% 3597
2023
Q4 		$129K Sell
29,000
-3,610
-11% -$10.7K ﹤0.01% 3787
2023
Q3 		$102K Buy
32,610
+2,605
+9% +$10.7K ﹤0.01% 3796
2023
Q2 		$155K Sell
30,005
-5,415
-15% -$32.2K ﹤0.01% 3765
2023
Q1 		$187K Buy
35,420
+5,020
+17% +$23.8K ﹤0.01% 3741
2022
Q4 		$85K Sell
30,400
-11,058
-27% -$36.6K ﹤0.01% 3826
2022
Q3 		$172K Buy
41,458
+600
+1% +$3.02K ﹤0.01% 3733
2022
Q2 		$164K Buy
40,858
+21,990
+117% +$83.1K ﹤0.01% 3710
2022
Q1 		$93K Sell
18,868
-3,350
-15% -$18.6K ﹤0.01% 3850
2021
Q4 		$155K Buy
+22,218
New +$173K ﹤0.01% 3827
2021
Q3 		– Sell
-11,413
Closed -$162K – 3920
2021
Q2 		$162K Buy
11,413
+123
+1% +$1.87K ﹤0.01% 3782
2021
Q1 		$186K Sell
11,290
-1,450
-11% -$27.9K ﹤0.01% 3714
2020
Q4 		$264K Sell
12,740
-1,830
-13% -$27.2K ﹤0.01% 3541
2020
Q3 		$111K Buy
14,570
+500
+4% +$4.15K ﹤0.01% 3628
2020
Q2 		$117K Sell
14,070
-5,518
-28% -$36.6K ﹤0.01% 3569
2020
Q1 		$97K Buy
19,588
+8,583
+78% +$42.4K ﹤0.01% 3538
2019
Q4 		$43K Buy
11,005
+5
+0% +$17 ﹤0.01% 3679
2019
Q3 		$33K Buy
+11,000
New +$49.2K ﹤0.01% 3677

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise's OCUL Position: Q2 2026 in Review

Ameriprise reduced its Ocular Therapeutix (OCUL) stake by 15% in Q2 2026, selling an estimated $59.4K and leaving 35,980 shares worth $353K. The position accounts for ﹤0.01% of the portfolio, ranked #3774.

Ameriprise first reported a position in OCUL in Q3 2019 and has held it in 27 quarters since. The position peaked at $6.49M in Q3 2025. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Ameriprise held 35,980 shares of Ocular Therapeutix worth $353K as of Q2 2026.
  • Ameriprise sold 6,553 Ocular Therapeutix shares in Q2 2026, an estimated $59.4K.
  • Ocular Therapeutix made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3774 holding.
  • Ameriprise first reported a position in Ocular Therapeutix in Q3 2019 and has held it in 27 quarters since.
  • Ameriprise's Ocular Therapeutix position peaked at $6.49M in Q3 2025.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.